Solu Therapeutics Announces Presentation of Trial in Progress on STX-0712 for Treatment of Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia at ASH Annual Meeting December 10, 2025
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition December 10, 2025
Solu Therapeutics Announces Presentation of Trial in Progress on STX-0712 for Treatment of Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia at ASH Annual Meeting December 3, 2025
Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with Urothelial Cancer Previously Treated with Enfortumab Vedotin November 24, 2025
AGC Biologics to Manufacture AAVantgarde’s Dual-Vector Gene Therapies for Inherited Retinal Disorders November 24, 2025
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update November 13, 2025
